Author:
Palmer Stephen,Lin Yi,Martin Thomas G.,Jagannath Sundar,Jakubowiak Andrzej,Usmani Saad Z.,Buyukkaramikli Nasuh,Phelps Hilary,Slowik Rafal,Pan Feng,Valluri Satish,Pacaud Lida,Jackson Graham
Funder
Janssen Research and Development, LLC
Legend Biotech USA Inc.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, et al. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer. 2020;8. https://doi.org/10.1136/jitc-2020-000648.
2. Rutherford MJ, Lambert PC, Sweeting MJ, Pennington B, Crowther MJ, Abrams KR, et al. NICE DSU technical support document 21: flexible methods for survival analysis. Sheffield, UK: Decision Support Unit, National Institute for Health and Care Excellence; 2020.
3. Ouwens M, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 2019;37:1129–38. https://doi.org/10.1007/s40273-019-00806-4.
4. Bullement A, Kearns B. Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. Health Services and Outcomes Research Methodology. 2022.
5. Jackson C, Stevens J, Ren S, Latimer N, Bojke L, Manca A, et al. Extrapolating survival from randomized trials using external data: a review of methods. Med Decis Mak. 2017;37:377–90. https://doi.org/10.1177/0272989X16639900.